ARS Pharmaceuticals shares surge 14.04% after-hours as Hussman Strategic Advisors buys 105,000 shares.

ARS Pharmaceuticals surged 14.04% in after-hours trading following a significant institutional purchase of 105,000 shares by Hussman Strategic Advisors Inc. on November 4, 2025. This buying activity, reported by MarketBeat, suggests renewed institutional confidence in the company amid ongoing regulatory challenges. While earlier news in September 2025 highlighted FDA rejections of its nasal spray and subsequent downgrades, the recent acquisition by a strategic advisor indicates potential optimism about the firm’s prospects, potentially signaling a shift in market sentiment.